Of the 540 (52.1%) CI patients with [18F]PM‐PBB3 ([18F]‐APN‐1607) PET, 95.0% (513/540) of patients were Tau‐positive, and over 90.0% of patients with VaD (3/3, 100.0%), FTLD (135/137, 98.5%), clinical AD (359/370, 97.0%), or DLB (12/13, 92.3%) were Tau‐positive, respectively. The gene discussed is MAPT; the disease is Alzheimer disease.